यूमेक्लिडिनियम और यूमेक्लिडिनियम और विलैंटेरोल का इंटरैक्शन

Paradoxical Bronchospasm As with other inhaled therapies, Umeclidinium and Vilanterol ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs.

Therefore, avoid coadministration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions ( 5.9 , 5.10 )] .

Paradoxical Bronchospasm As with other inhaled therapies, Umeclidinium ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs.

Therefore, avoid coadministration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions ( 5.4 , 5.5 )] .

Acute symptoms should be treated with an inhaled, short-acting beta 2 -agonist.

If Umeclidinium ELLIPTA no longer controls symptoms of bronchoconstriction; the patient’s inhaled, short-acting beta 2 -agonist becomes less effective; or the patient needs more short-acting beta 2 -agonist than usual, these may be markers of deterioration of disease.